The innate immune response in fetal lung mesenchymal cells targets VEGFR2 expression and activity

Rachel M Medal1, Amanda M Im2, Yasutoshi Yamamoto2

  • 1Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California; and.

Insights

Bacterial endotoxin lipopolysaccharide (LPS) alters fetal lung development by affecting mesenchymal cells. LPS reduces vascular endothelial growth factor receptor 2 (VEGFR2) signaling, impairing lung structure formation.

Area of Science:

  • Developmental biology
  • Immunology
  • Molecular biology

Background:

  • Inflammatory mediators disrupt lung development in preterm infants.
  • Mesenchymal cell response to microbial stimuli is not well understood.

Purpose of the Study:

  • To investigate the genome-wide innate immune response of fetal lung mesenchymal cells to lipopolysaccharide (LPS).
  • To determine the role of vascular endothelial growth factor receptor 2 (VEGFR2) in lung development and its modulation by LPS.

Main Methods:

  • Gene expression profiling using Affymetrix MoGene 1.0st arrays.
  • Stimulation of mesenchymal cells with LPS and VEGF-A.
  • Assessment of cell migration, signaling pathways (ERK/AKT, FOXO3A), and 3D structure formation in coculture models.

Main Results:

  • LPS induced unique innate immune transcripts, primarily chemokines, with differential responses based on developmental stage (E11, E15, E18).
  • LPS inhibited expression of key genes, including VEGFR2, in fetal lung mesenchymal cells.
  • VEGF-A stimulation increased mesenchymal cell migration and activated ERK/AKT pathways.
  • VEGFR2 inhibition and LPS treatment both reduced 3D lung structure formation.

Conclusions:

  • Fetal lung mesenchymal cells express functional VEGFR2, responding to VEGF-A.
  • LPS exposure impairs lung development by downregulating VEGFR2 and inhibiting 3D structure formation.
  • Reduced VEGF signaling in lung mesenchyme is a novel mechanism for inflammation-induced developmental defects.